Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (180 pages) : , illustrations, tables

ISBN: 9780128013441 , 0128013443 , 9780128014875 , 0128014873

Note: Cover -- Title Page -- Copyright Page -- Dedication -- Contents -- List of Contributors -- Preface -- Chapter 1 - Angiogenesis in Peripheral Artery Disease: Focus on Growth Factor Therapy -- Introduction -- Growth factor therapy in peripheral artery disease -- Fibroblast growth factor -- Vascular endothelial growth factor -- Hepatocyte growth factor -- Hypoxia-Induced Factor-1 Alpha -- Summary of Growth Factor Therapy in PAD -- References -- Chapter 2 - Regenerative Cell Therapy: Historical Background and Future Directions -- Introduction -- Historical overview -- Current treatments for PAD -- Preclinical and clinical trials for PAD -- Future direction in PAD -- Conclusions -- References -- Chapter 3 - Bone Marrow-Derived Cells: From the Laboratory to the Clinic -- Isolation and characterization of bone marrow mononuclear cells -- Definition and Composition of BMMNC -- Isolation of BMMNC -- Preclinical evidence for BMMNC benefits in PAD -- Potential mechanisms of BMMNC in PAD -- Reconstruction of Vascular Endothelial Architecture -- Stabilization of Neovasculature via Pericyte Differentiation -- Secretion of Proangiogenic Factors -- Clinical trials using BMMNC for CLI patients -- Overview of BMMNC in CLI -- Safety of BMMNC in CLI -- Primary Endpoints for BMMNC in CLI -- Secondary Endpoints for BMMNC in CLI -- Clinical trials using subsets of BMMNC for CLI patients -- Conclusions and future directions -- References -- Chapter 4 - Mesenchymal Stem Cells for Treatment of Peripheral Vascular Disease -- Clinical need -- Mesenchymal stem cells -- Mesenchymal stem cells and angiogenesis -- Comparison of isolated mesenchymal stem cells with other cell populations: preclinical studies -- Comparison of isolated mesenchymal stem cells with other cell populations: clinical studies -- Clinical trials design considerations. , Treatment of critical limb ischemia -- Unselected mesenchymal stem cell populations -- Comparison of mesenchymal stem cells with other cell types -- Mesenchymal stem cells for intermittent claudication -- Metaanalysis -- Isolated mesenchymal stem cells -- Remaining challenges -- Conclusions -- References -- Chapter 5 - Endothelial Progenitor Cells for Vascular Medicine -- Endothelial progenitor cell -- Definition of EPCs -- Tissue EPCs Versus Circulating EPCs -- Hematopoietic EPCs Versus Nonhematopoietic EPCs -- Hematopoietic EPCs (h-EPCs) -- Colony-Forming EPCs Versus Non-Colony-Forming EPCs -- Colony-Forming EPCs -- Non-Colony-Forming EPCs -- Role of EPCs in Postnatal Neovascularization -- Direct EPC Contribution to Neovascularization -- Indirect EPC Contribution to Neovascularization -- EPC-based therapeutic angiogenesis -- EPC Transplantation in Animal Models -- EPC Transplantation in Clinical Trials -- Problems in EPC Transplantation -- Future Strategies for EPC-Based Therapeutic Angiogenesis -- Summary -- References -- Chapter 6 - Mature Cell Activation -- Disclosures -- References -- Chapter 7 - Imaging for Regenerative Therapy for PAD -- Introduction -- Magnetic resonance imaging and spectroscopy -- Skeletal Muscle Perfusion -- Skeletal Muscle Deoxygenation -- Susceptibility-Weighted MR Oximetry -- MR Spectroscopic Measures of Tissue Energetics -- Combined Approaches -- Limitations -- Contrast-enhanced ultrasound -- Contrast Ultrasound Imaging Technology -- Perfusion Imaging With Contrast-Enhanced Ultrasound -- CEU Perfusion Imaging in PAD -- CEU Assessment of Cell Therapy for PAD -- Limitations -- Radionuclide imaging -- Radionuclide Imaging Technology -- Assessment of Flow and Perfusion -- Radionuclide Imaging of Angiogenesis and Cell Therapy -- Limitations -- Conclusions -- References. , Chapter 8 - Endpoint Assessment for Cell Therapy in Patients with Intermittent Claudication and Critical Limb Ischemia -- Introduction -- Endpoints used -- Review of prior studies -- IC -- CLI -- Issues with endpoints -- Analysis of outcomes -- Group efforts to define endpoints -- Path forward -- Conclusions -- References -- Chapter 9 - Endpoint Assessment for Critical Limb Ischemia for Cellular Therapy -- Introduction -- CLI treatment goals -- Endpoint assessment options -- Amputation/Amputation-Free Survival -- Risk Factors Related to Amputation and AFS -- Rest Pain/Wound Healing -- Endpoint Time Frame for Amputation -- Rest Pain -- Wound Healing -- Quality of Life -- Surrogate Outcome Measures -- Prevention of Need for Revascularization -- Composite Measures -- Endpoint Assessment in Recent CLI Studies Using Cellular Therapy -- Summary -- References -- Index -- Back cover.

Language: English